Oak Ridge Investments’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-4,090
Closed -$805K – 152
2022
Q3
$805K Hold
4,090
– – 0.12% 132
2022
Q2
$875K Hold
4,090
– – 0.13% 126
2022
Q1
$1.16M Sell
4,090
-10
-0.2% -$3.08K 0.13% 124
2021
Q4
$1.54M Sell
4,100
-240
-6% -$93.2K 0.13% 119
2021
Q3
$1.79M Sell
4,340
-1,128
-21% -$468K 0.16% 118
2021
Q2
$2.02M Sell
5,468
-43
-0.8% -$14.4K 0.18% 115
2021
Q1
$1.6M Sell
5,511
-314
-5% -$87.3K 0.15% 115
2020
Q4
$1.46M Sell
5,825
-151
-3% -$36K 0.13% 125
2020
Q3
$1.35M Buy
5,976
+28
+0.5% +$5.81K 0.11% 123
2020
Q2
$1.04M Sell
5,948
-56
-0.9% -$8.94K 0.09% 125
2020
Q1
$758K Buy
6,004
+1,708
+40% +$256K 0.08% 130
2019
Q4
$656K Buy
+4,296
New +$595K 0.05% 155

Other funds holding CRL

Oak Ridge Investments's CRL Position: Q4 2022 in Review

Oak Ridge Investments sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 4,090 shares — an estimated $805K sold.

Oak Ridge Investments first reported a position in CRL in Q4 2019 and held it in 12 quarters. The position peaked at $2.02M in Q2 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

  • Oak Ridge Investments reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
  • Oak Ridge Investments sold 4,090 Charles River Laboratories shares in Q4 2022, an estimated $805K.
  • Oak Ridge Investments first reported a position in Charles River Laboratories in Q4 2019 and held it in 12 quarters.
  • Oak Ridge Investments's Charles River Laboratories position peaked at $2.02M in Q2 2021.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Oak Ridge Investments's 13F filing for Q4 2022, filed 24 Jan 2023.